Ramot

Ramot is the technology transfer company of Tel Aviv University and one of the most active tech-transfer engines in Israel. Its Momentum Fund deploys capital into the earliest stages of commercializing university research, often at the moment when an academic project becomes a credible startup.

The thesis is structurally different from a conventional venture firm. Ramot exists to license, spin out, and finance technology emerging from Tel Aviv University’s labs, with the Momentum Fund providing the rapid capital that bridges from academic discovery to a company that can attract institutional investors. Portfolio activity in healthcare concentrates on biotech, medical devices, AI/ML in healthcare, and life sciences tools, almost always built around founders with deep academic credentials who are emerging from significant research programs. AI shows up across the portfolio in line with the university’s strength in computer science, mathematics, and data-intensive research.

Checks fall below two hundred and fifty thousand dollars at the Pre-Seed and Seed stages, designed to underwrite the earliest commercialization work rather than to lead institutional rounds. Geography is structured around technology coming out of Tel Aviv University, with companies typically targeting global markets in the US and Europe. Ramot is positioned as a launching pad rather than an end-state investor, and successful portfolio companies are expected to graduate quickly into syndicated rounds led by external venture investors.

The team operates with the discipline of a tech-transfer organization that has been doing this for decades. Founders work with experienced licensing and commercialization staff, and the engagement is substantive on questions of IP, licensing structures, and the translation of academic work into a viable company. The diligence is grounded in technical and IP analysis, and the relationships extend deep into the university’s research community.

In practice, Ramot’s value to founders is unusual. It owns or co-owns the foundational IP, it can structure the licensing arrangements, and it is willing to put capital behind the spinout. That bundle is hard to replicate from outside the university system. The fund is direct about scope. It does not invest in companies unaffiliated with Tel Aviv University, and the structure of the relationship is meaningfully different from a conventional VC engagement. For academic founders coming out of Tel Aviv University with biotech, medical device, life sciences tools, or AI healthcare research, Ramot is the natural and often essential first partner. The conversations are technical, the structures are institutional, and the founders who do well here are those who treat Ramot as an integral commercial partner rather than as a passive licensor. The path forward usually involves bringing in venture investors quickly, and Ramot is constructive about that handoff rather than territorial about it.